|Day Low/High||48.56 / 51.54|
|52 Wk Low/High||6.34 / 56.74|
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
Covered call options provide downside protection for holders of the underlying stock and can yield nice profits, too.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
Trade continues to be listless and in a relatively tight trading range as markets try to end a solid week for investors. Equities are pretty flat across the board. I would not be surprised to see some profit taking later in the day. Cashing in some ...
Pre-market futures are still pointing to a slightly up open as we try to end the trading week hitting more all-time highs. Fourth quarter earnings results continue to flow across the wires. Big financial firms have kicked off the earnings season thi...
Putting buy-writes in your investing 'toolbox' seems one route to becoming a better investor in 2020.
The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
Shares of this biotech company are up 75% for 2019, despite recent weakness.
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
The biotech sector has seen a big rally, but there are still opportunities.
Prospects for acquisition activity in the sector are improving.
Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.
Action runs counter to pattern, leaving market players wondering what to do.
We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.
The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.